Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
- Resource Type
- Source
- The New England journal of medicine, 380 (26
- Subject
Male Vital capacity Indoles Vital Capacity Administration, Oral 2700 General Medicine 030204 cardiovascular system & hematology Pulmonary function testing law.invention oral Idiopathic pulmonary fibrosis chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law SENSCIS Trial Investigators CYCLOPHOSPHAMIDE Clinical endpoint scleroderma 030212 general & internal medicine Enzyme Inhibitors 11 Medical and Health Sciences lung diseases Lung Diseases, Interstitial -- drug therapy -- etiology -- physiopathology 10051 Rheumatology Clinic and Institute of Physical Medicine General Medicine respiratory system Sciences bio-médicales et agricoles Middle Aged Protein-Tyrosine Kinases MANIFESTATIONS Disease Progression Nintedanib Female TYROSINE KINASE INHIBITOR Life Sciences & Biomedicine CLINICAL-TRIALS Adult Diarrhea medicine.medical_specialty FIBROBLASTS 610 Medicine & health Placebo administration behavioral disciplines and activities 03 medical and health sciences FEV1/FVC ratio Medicine, General & Internal Double-Blind Method Internal medicine General & Internal Medicine Enzyme Inhibitors -- adverse effects -- therapeutic use SCORE medicine Humans Indoles -- adverse effects -- therapeutic use Scleroderma, Systemic -- complications -- drug therapy Science & Technology Scleroderma, Systemic Protein-Tyrosine Kinases -- antagonists & inhibitors business.industry MORTALITY interstitial PULMONARY-FUNCTION systemic STANDARDIZATION medicine.disease EFFICACY respiratory tract diseases body regions chemistry adult diarrhea disease progression double-blind method enzyme inhibitors female humans indoles lung diseases, interstitial male middle aged protein-tyrosine kinases scleroderma, systemic vital capacity business Lung Diseases, Interstitial Diarrhea -- chemically induced - Language
- English